Trial Profile
A Randomized, Phase II Trial of Icotinib Versus Observation as Adjuvant Treatment in Stage IB Non-Small Cell Lung Cancer Harboring Activating Epidermal Growth Factor Receptor Mutation
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 18 Jul 2022
Price :
$35
*
At a glance
- Drugs Icotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms CORIN
- 07 Jun 2022 Results assessing adjuvant therapy with icotinib improves the clinical outcome compared with observation in patients with EGFR mutation-positive resected stage IB NSCLC presented at the 58th Annual Meeting of the American Society of Clinical Oncology
- 02 Mar 2021 Planned End Date changed from 1 Jan 2020 to 1 Dec 2025.
- 02 Mar 2021 Planned primary completion date changed from 1 Jan 2020 to 1 Dec 2025.